ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

Financial Performance - Regeneron's Q3 2024 sales increased by only 3% year-over-year, with Eylea sales at $392 million, missing consensus estimates of$415 million to $425 million [1] - Eylea sales were adversely impacted by a lower net selling price compared to Q3 2023 [1] - Regeneron's stock price fell$84.59, or 9%, to close at $838.20 per share on October 31, 2024 [1] Legal and Regulatory Issues - The DOJ alleges that Regeneron inflated the average sales price of Eylea, inappropriately increasing Medicare reimbursements [2] - Regeneron's stock price declined by$31.50, more than 3%, over two trading days following the DOJ announcement, closing at $904.70 per share on April 12, 2024 [2] - A securities class action lawsuit has been filed against Regeneron on behalf of purchasers of its securities between November 2, 2023, and October 30, 2024 [3] - The DOJ filed a complaint against Regeneron under the False Claims Act for failing to report millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees [4] Legal Representation and Investor Participation - Investors who purchased Regeneron securities during the Class Period may seek to be appointed as a lead plaintiff representative by March 10, 2025 [4] - Berger Montague, a pioneer in securities class action litigation, is representing investors in this case [6]